<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Metagenomi Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock</link>
<description>Latest news and press releases for Metagenomi Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 28 May 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/metagenomi-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683598f378dffbe2df105a4d.webp</url>
<title>Metagenomi Therapeutics, Inc.</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock</link>
</image>
<item>
<title>Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-inc-to-present-at-the-jefferies-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-inc-to-present-at-the-jefferies-global-healthcare-conference</guid>
<pubDate>Thu, 28 May 2026 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 4, 2026, at 7:35 a.m. ET.</description>
</item>
<item>
<title>Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-reports-business-updates-and-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-reports-business-updates-and-first-quarter-2026-financial-results</guid>
<pubDate>Mon, 11 May 2026 20:05:00 GMT</pubDate>
<description>On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equivalents, and available-for-sale marketable securities as of March 31, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Cali</description>
</item>
<item>
<title>Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-inc-announces-publication-in-nature-structural-and-molecular-biology-highlighting-proprietary-compact-crispr-nuclease-with-enhanced-genome-editing-efficiency</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-inc-announces-publication-in-nature-structural-and-molecular-biology-highlighting-proprietary-compact-crispr-nuclease-with-enhanced-genome-editing-efficiency</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company</description>
</item>
<item>
<title>Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-reports-business-updates-and-full-year-2025-financial-results-64</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-reports-business-updates-and-full-year-2025-financial-results-64</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for</description>
</item>
<item>
<title>Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-inc-to-present-at-the-46th-annual-td-cowen-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-therapeutics-inc-to-present-at-the-46th-annual-td-cowen-healthcare-conference</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. E</description>
</item>
<item>
<title>Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-announces-corporate-name-change-133000842</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-announces-corporate-name-change-133000842</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026 Cash runway anticipated through 4Q 2027 EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”)</description>
</item>
<item>
<title>Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-present-preclinical-data-supporting-120000890</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-present-preclinical-data-supporting-120000890</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025,</description>
</item>
<item>
<title>Metagenomi to Present at Jefferies Global Healthcare Conference in London</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-present-jefferies-global-healthcare-130000130</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-present-jefferies-global-healthcare-130000130</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A, President and Chief Executive Officer of Metagenomi, will be presenting at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:30 a.m. GMT. A live webcast will be available in the inv</description>
</item>
<item>
<title>Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-third-quarter-2025-210200080</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-third-quarter-2025-210200080</guid>
<pubDate>Tue, 11 Nov 2025 21:02:00 GMT</pubDate>
<description>New MGX-001 preclinical data supports advancement into clinical development; Demonstrated curative FVIII activity in non-human primates Prioritized later-stage preclinical pipeline including wholly-owned MGX-001 hemophilia A program; pre-IND meeting for MGX-001 expected in 4Q 2025 with IND/CTA submissions expected in 4Q 2026 Organizational restructuring reduced workforce by 25%; Capital allocation strategy anticipated to extend cash runway into the 4Q 2027 Jian Irish, Ph.D., M.B.A., currently Pr</description>
</item>
<item>
<title>Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-presents-preclinical-data-mgx-210100999</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-presents-preclinical-data-mgx-210100999</guid>
<pubDate>Tue, 11 Nov 2025 21:01:00 GMT</pubDate>
<description>MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding data from t</description>
</item>
<item>
<title>Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-business-updates-second-200500152</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-business-updates-second-200500152</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Presented three abstracts at American Society of Gene & Cell Therapy (“ASGCT”) demonstrating early proof-of-concept data across multiple gene editing technologies Well capitalized with $205.0 million in cash, cash equivalents and available-for-sale marketable securities as of June 30, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to</description>
</item>
<item>
<title>Metagenomi Appoints Laurence Reid, PhD to its Board of Directors</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-appoints-laurence-reid-phd-200500588</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-appoints-laurence-reid-phd-200500588</guid>
<pubDate>Mon, 11 Aug 2025 20:05:00 GMT</pubDate>
<description>Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategyEMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to its Board of Directors. “We are delighted to we</description>
</item>
<item>
<title>Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-presents-data-highlighting-advancements-100000825</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-presents-data-highlighting-advancements-100000825</guid>
<pubDate>Wed, 14 May 2025 10:00:00 GMT</pubDate>
<description>- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation - EMERYVILLE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company c</description>
</item>
<item>
<title>Metagenomi Reports Business Updates and First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-business-updates-first-203000953</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-business-updates-first-203000953</guid>
<pubDate>Tue, 13 May 2025 20:30:00 GMT</pubDate>
<description>- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medic</description>
</item>
<item>
<title>Metagenomi to Present at Upcoming Scientific Meetings</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-present-upcoming-scientific-meetings-110000145</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-present-upcoming-scientific-meetings-110000145</guid>
<pubDate>Fri, 02 May 2025 11:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (A</description>
</item>
<item>
<title>Metagenomi Reports Business Updates and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-business-updates-full-200500321</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-reports-business-updates-full-200500321</guid>
<pubDate>Mon, 17 Mar 2025 20:05:00 GMT</pubDate>
<description>Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to lead optimization with plans to declare one to two development candidates (DCs) in 2025 Well capitalized w</description>
</item>
<item>
<title>Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-announces-publication-nature-communications-101900932</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-announces-publication-nature-communications-101900932</guid>
<pubDate>Thu, 13 Mar 2025 10:19:00 GMT</pubDate>
<description>Achieved targeted integration of a large, therapeutically relevant gene into the genome of human cells with compact CAST system AI-driven metagenomics platform facilitated discovery of CAST system with activity in human cells Expression of the compact CAST system from a single 'all-in-one' mRNA design represents a first-in-class approach to simplifying delivery for therapeutic applications Additional updates on further advancements in novel large gene integration technology anticipated in 2025 E</description>
</item>
<item>
<title>Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-highlights-progress-across-therapeutic-portfolio-and-outlines-anticipated-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-highlights-progress-across-therapeutic-portfolio-and-outlines-anticipated-milestones</guid>
<pubDate>Thu, 16 Jan 2025 05:00:00 GMT</pubDate>
<description>MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency</description>
</item>
<item>
<title>Metagenomi Announces New Appointment to its Board of Directors</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-announces-new-appointment-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-announces-new-appointment-to-its-board-of-directors</guid>
<pubDate>Wed, 15 Jan 2025 05:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative</description>
</item>
<item>
<title>Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting</title>
<link>https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-presents-updated-preclinical-data-in-hemophilia-a-at-american-society-of-hematology-ash-66th-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/metagenomi-inc-common-stock/news/metagenomi-presents-updated-preclinical-data-in-hemophilia-a-at-american-society-of-hematology-ash-66th-annual-meeting</guid>
<pubDate>Mon, 09 Dec 2024 05:00:00 GMT</pubDate>
<description>Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow</description>
</item>
</channel>
</rss>